Unique ID issued by UMIN | UMIN000013373 |
---|---|
Receipt number | R000015574 |
Scientific Title | The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi- Harada disease. |
Date of disclosure of the study information | 2014/04/01 |
Last modified on | 2023/03/27 17:17:06 |
The combination therapy of prednisolone and cyclosporine for initial onset
of Vogt-Koyanagi- Harada disease.
PSL/CYA combination therapy for VKH disease
The combination therapy of prednisolone and cyclosporine for initial onset
of Vogt-Koyanagi- Harada disease.
PSL/CYA combination therapy for VKH disease
Japan |
Vogt-Koyanagi- Harada disease
Ophthalmology |
Others
NO
To investigate the efficacy of the combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease
Safety,Efficacy
Proportion of subjects showing recurrences of uveitis with VKH disease
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
1.The group given only prednisolone
mPSL 1000mg Intravenous Infusion 3 days
PSL 0.6~0.7 mg/kg Oral Administration 10 days
PSL 0.5~0.6 mg/kg Oral Administration 10 days
PSL 0.4~0.5 mg/kg Oral Administration 10 days
PSL 0.3~0.4 mg/kg Oral Administration 4 weeks
PSL 0.2~0.3 mg/kg Oral Administration 4 weeks
PSL 0.1~0.2 mg/kg Oral Administration 4 weeks
PSL 0.05~0.1 mg/kg Oral Administration 8 weeks
PSL 0.05~0.1 mg/kg every other day Oral Administration 4 weeks
2.The group given combination of prednisolone and cyclosporine
In addition to "1.", CYA 3mg/kg is administered from day 4
20 | years-old | <= |
70 | years-old | >= |
Male and Female
1.Patients of initial onset VKH disease who present all of a) to d)
a) Within 4 weeks from disease onset
b) Showing anterior chamber cells maximum 2+
c) Showing typical serous retinal detachment
d) Without sunset glow fundus
2.Complete or incomplete type of VKH disease
3.Showing cerebrospinal fluid pleocytosis or meningeal irritation signs except headache alone
4.Who can recieve the treatment within 4 weeks from the disease onset
1.Renal dysfunction
2.Immunosuppressant treatment including steroid
3.Immunocompromised condition
4.Females who are pregnant or lactating patients or who are suspicious of pregnant
5.Malignant neoplasm
6.Intraocular surgery (except for cataract surgery) or glaucoma surgery previously, or speculate to be required in the periods of this study
7.Investigator declare a subject ineligible for any sound reasons
120
1st name | |
Middle name | |
Last name | Kenichi Namba |
Hokkaido University Graduate School of Medicine
Department of Ophthalmology
Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan
011-706-5944
knamba@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Kazuomi Mizuuchi |
Hokkaido University Graduate School of Medicine
Department of Ophthalmology
Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan
011-706-5944
mizuuchi@peach.plala.or.jp
Hokkaido University Graduate School of Medicine
Hokkaido University Graduate School of Medicine
Self funding
Kyushu University Graduate School of Medicine
National Defense Medical College Hospital
Kagoshima University Graduate School of Medicine
Kyorin University Hospital
Yamaguchi University Hospital
Kanazawa University Hospital
Graduate School of Medicine, The University of Tokyo
Kochi Medical School Hospital
Kobe University Hospital
NO
2014 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 04 | Month | 01 | Day |
2023 | Year | 03 | Month | 27 | Day |
2014 | Year | 03 | Month | 07 | Day |
2023 | Year | 03 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015574